China IP office issues CRISPR patent

Intellia Therapeutics Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP) said China's State Intellectual Property Office (SIPO) has granted a broad patent covering CRISPR/Cas9 single-guide gene editing technology. The patent covers IP from the Regents of the University of California, the University of Vienna and Emmanuelle Charpentier. Each company holds a license to the IP.

The companies said the patent covers non-cellular and cellular settings, including in human and other eukaryotic cells, and "in producing medicines for treating disease.”...